Helicobacter pylori: testing and treatment

References

• Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol.93, 2330–2338 (1998).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection–the Maastricht 3 Consensus Report. Gut56, 772–781 (2001).
   Google Scholar
• Vilaichone R-K, Mahachai V, Graham DM. Helicobacter pylori diagnosis and management. Gastroenterol. Clin. N. Am.35, 229–247 (2006).
   PubMedGoogle Scholar
• Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J. Infect. Dis.181(4), 1359–1363 (2000).
   PubMed Web of Science ®Google Scholar
• Laine L, Lewin D, Naritoku W, Estrada R, Cohen H. Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. Gastrointest. Endosc.44(5), 523–526 (1996).
   PubMed Web of Science ®Google Scholar
• Laine L, Nathwani RA, Naritoku W. The effect of GI bleeding on Helicobacter pylori diagnostic testing: a prospective study at the time of bleeding and 1 month later. Gastrointest. Endosc.62(6), 853–859 (2005).
   PubMedGoogle Scholar
• El-Zimaity H, Segura AM, Genta RM, Graham DY. Histologic assessment of Helicobacter pylori status after therapy: comparison of Giemsa, Diff-Quik, and Genta stains. Mod. Pathol.11(3), 188–191 (1998).
   Google Scholar
• Vakil N. Helicobacter pylori treatment: a practical approach. Am. J. Gastroenterol.101, 497–499 (2006).
   PubMed Web of Science ®Google Scholar
• Graham DY, Opekun AR, Hammoud F et al. Studies regarding the mechanism of false-negative urea breath tests with PPIs. Am. J. Gastroenterol.98(5), 1005–1009 (2003).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am. J. Gastroenterol.101(4), 848–863 (2006).
   PubMed Web of Science ®Google Scholar
• Chey WD, Murthy U, Toskes PP, Carpenter S, Laine L. The 13C-urea blood test accurately detects active Helicobacter pylori infection: a United States, multicenter trial. Am. J. Gastroenterol.94(6), 1522–1524 (1999).
   PubMedGoogle Scholar
• Vaira D, Vakil N, Menegatti M et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann. Intern. Med.136, 280–287 (2002).
   PubMed Web of Science ®Google Scholar
• Hooton C, Keohane J, Clair J et al. Comparison of three stool antigen assays with the 13C-urea breath test for the primary diagnosis of Helicobacter pylori infection and monitoring treatment outcome. Eur. J. Gastroenterol. Hepatol.18(6), 595–599 (2006).
   PubMedGoogle Scholar
• Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am. J. Gastroenterol.101(8), 1921–1930 (2006).
   PubMedGoogle Scholar
• Vaira D, Malfertheiner P, Megraud F et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet354, 30–33 (1999).
   PubMedGoogle Scholar
• Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am. J. Gastroenterol.91, 1138–1144 (1996).
   PubMed Web of Science ®Google Scholar
• Xia HH, Kalantar JS, Wyatt JM et al. High sensitivity and specificity of a laboratory-based serological test, pylori DTect ELISA, for detection of Helicobacter pylori infection. Diagn. Microbiol. Infect. Dis.36(2), 69–74 (2000).
   PubMedGoogle Scholar
• Cohen H, Rose S, Lewin DN et al. Accuracy of four commercially available serologic tests, including two office-based tests and a commercially available 13C-urea breath test, for diagnosis of Helicobacter pylori. Helicobacter4(1), 49–53 (1999).
   PubMedGoogle Scholar
• Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann. Intern. Med.129(7), 547–550 (1998).
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Soo S, Deeks J et al. Eradication of Helicobacter pylori for nonulcer dyspepsia. Cochrane Database Syst. Rev.2, CD002096 (2006).
   Google Scholar
• Lane JA, Murray LJ, Noble S et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter project: randomised controlled trial. Br. Med. J.332(7535), 187–188 (2006).
   PubMedGoogle Scholar
• Vakil N, Talley NJ, Stolte M, Sundin M, Junghard O, Bolling-Sternevald E. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Aliment. Pharmacol. Ther.24, 55–63 (2006).
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet367, 2086–2100 (2006).
   PubMed Web of Science ®Google Scholar
• Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and Helicobacter pylori infection in the United States. Am. J. Epidemiol.163(2), 127–134 (2006).
   PubMedGoogle Scholar
• Kaptan K, Beyan C, Ural AU et al. Helicobacter pylori-is it a novel causative agent in Vitamin B12 deficiency? Arch. Intern. Med.160(9), 1229–1230 (2000).
   PubMedGoogle Scholar
• Goodman KJ, Joyce SL, Ismond KP. Extragastric diseases associated with Helicobacter pylori infection. Curr. Gastroenterol. Rep.8(6), 458–464 (2006).
   PubMedGoogle Scholar
• Kuwana M, Ikeda Y. Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies. Int. J. Hematol.84(4), 309–315 (2006).
   PubMed Web of Science ®Google Scholar
• Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y. Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica91(10), 1436–1437 (2006).
   PubMedGoogle Scholar
• Pasceri V, Patti G, Cammarota G, Pristipino C, Richichi G, Di Sciascio G. Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am. Heart J.151(6), 1215–1222 (2006).
   PubMed Web of Science ®Google Scholar
• Zumkeller N, Brenner H, Zwahlen M, Rothenbacher D. Helicobacter pylori infection and colorectal cancer risk; a meta-analysis. Helicobacter11(2), 75–80 (2006).
   PubMed Web of Science ®Google Scholar
• Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther.21(12), 1411–1418 (2005).
   PubMed Web of Science ®Google Scholar
• Quan C, Talley NJ. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am. J. Gastroenterol.97(12), 1950–1961 (2002).
   Google Scholar
• Talley NJ, Vakil N, Moayyedi P. AGA technical review on the evaluation of dyspepsia. Gastroenterology129, 1756–1780 (2005).
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Nelis GF, Klinkenberg-Knol EC et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut53, 12–20 (2004).
   PubMed Web of Science ®Google Scholar
• Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther.20, 99–107 (2004).
   PubMed Web of Science ®Google Scholar
• Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a PPI, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment. Pharmacol. Ther.14(5), 603–609 (2000).
   PubMed Web of Science ®Google Scholar
• Gene E, Calvet X, Azagra R, Gisbert JP. Triple versus quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment. Pharmacol. Ther.17(9), 1137–1143 (2003).
   PubMed Web of Science ®Google Scholar
• Graham DY, Belson G, Abudayyeh S, Osato MS, Dore MP, El-Zimaity HM. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig. Liver Dis.36(6), 384–387 (2004).
   PubMedGoogle Scholar
• Fischbach LA, van Zanten SV, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first line anti-Helicobacter pylori quadruple therapies. Aliment. Pharmacol. Ther.20, 1071–1082 (2004).
   PubMed Web of Science ®Google Scholar
• Laine L, Frantz JE, Baker A, Neil GA. A United States multicentre trial of dual and PPI-based triple therapies for Helicobacter pylori. Aliment. Pharmacol. Ther.11(5), 913–917 (1997).
   PubMed Web of Science ®Google Scholar
• Vakil N. Helicobacter pylori: factors affecting eradication and recurrence. Am. J. Gastroenterol.100(11), 2393–2394 (2005).
   PubMed Web of Science ®Google Scholar
• Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy – results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther.17(1), 99–109 (2003).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Silliman NP, Wang W et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann. Intern. Med.136(1), 13–24 (2002).
   Google Scholar
• Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch. Intern. Med.161(9), 1217–1220 (2001).
   PubMed Web of Science ®Google Scholar
• Laine L, Fennerty MB, Osato M et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am. J. Gastroenterol.95, 3393–3398 (2000).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Matsuo K, Ito H et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am. J. Med.119(3), 217–224 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Matsuo K, Sawaki A, Ito H et al. Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment. Pharmacol. Ther.24, 273–280 (2006).
   PubMed Web of Science ®Google Scholar
• Wang X, Fang JY, Lu R, Sun DF. A meta-analysis: comparison of esomeprazole and other PPIs in eradicating Helicobacter pylori. Digestion73(2–3), 178–186 (2006).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Dominguez-Munoz A, Dominguez-Martin A, Gisbert JL, Marcos S. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am. J. Gastroenterol.100(9), 2393–2394 (2005).
   PubMedGoogle Scholar
• Janssen MJ, Laheij RJ, de Boer WA, Jansen JB. Meta-analysis: the influence of pre-treatment with a PPI on Helicobacter pylori eradication. Aliment. Pharmacol. Ther.21, 341–345 (2005).
   PubMed Web of Science ®Google Scholar
• Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol.101, 488–496 (2006).
   PubMed Web of Science ®Google Scholar
• Nista E, Candelli M, Zocco MA et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am. J. Gastroenterol.101(9), 1985–1990 (2006).
   PubMedGoogle Scholar
• Gisbert JP, Castro-Fernandez M, Bermejo F et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am. J. Gastroenterol.101(2), 243–247 (2006).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. ‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter8(2), 90–94 (2003).
   PubMed Web of Science ®Google Scholar
• Wong WM, Gu Q, Lam SK et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment. Pharmacol. Ther.17(4), 553–560 (2003).
   PubMed Web of Science ®Google Scholar
• Qasim A, Sebastian S, Thornton O et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment. Pharmacol. Ther.21, 91–96 (2005).
   PubMed Web of Science ®Google Scholar
• Zullo A, Vaira D, Vakil N et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment. Pharmacol. Ther.17(5), 719–726 (2003).
   PubMed Web of Science ®Google Scholar
• Zullo A, Gatta L, De Francesco V et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment. Pharmacol. Ther.21(12), 1419–1424 (2005).
   PubMed Web of Science ®Google Scholar
• Di Mario F, Aragona G, Bo ND et al. Use of lactoferrin for Helicobacter pylori eradication. Preliminary results. J. Clin. Gastroentrol.36(5), 396–398 (2003).
   PubMed Web of Science ®Google Scholar
• Di Mario F, Aragona G, Dal N et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig. Liver Dis.35(10), 706–710 (2003).
   PubMedGoogle Scholar
• Zullo A, De Francesco V, Scaccianoce G et al. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study. Dig. Liver Dis.37(7), 496–500 (2005).
   PubMedGoogle Scholar
• Guttner Y, Windsor HM, Viiala CH, Marshall BJ. Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment. Pharmacol. Ther.17(1), 125–129 (2003).
   PubMed Web of Science ®Google Scholar
• Gotoh A, Akamatsu T, Shimizu T et al. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter7(3), 183–191 (2002).
   PubMedGoogle Scholar
• Canducci F, Cremonini F, Armuzzi A et al. Probiotics and Helicobacter pylori eradication. Dig. Liver Dis.34(Suppl. 2), S81–S83 (2002).
   PubMedGoogle Scholar